Korro Bio, Inc. — Investor Relations & Filings

Korro Bio, Inc. is a biopharmaceutical company focused on the discovery and development of a new class of precision genetic medicines that utilize RNA editing. The company's proprietary platform, OPERA (Oligonucleotide Promoted Editing of RNA), employs chemically modified oligonucleotides to redirect the body's naturally occurring ADAR (Adenosine Deaminase Acting on RNA) editing process. This approach enables the precise, single-base editing of RNA to repair proteins affected by genetic mutations or to modulate biological pathways. Korro Bio is advancing a pipeline of drug candidates to address a broad range of rare and prevalent diseases, with an initial program targeting Alpha-1 Antitrypsin Deficiency (AATD).